While data from the SOLVD and CHARM trials seem to show a positive correlation between ACE inhibitors or angiotensin receptor blockers (ARBs) and risk of cancer development, in a large meta-analysis, RAAS blockers showed a favorable effect on all cancer endpoints [39•]. This evidence concerns the gene ACE and cancer.